Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spray Clear all
Terminated Phase 2 Interventional Results available

Sublingual Fentanyl for the Management of Breakthrough Pain

NCT02514252
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests, Study Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

E-Selectin Nasal Spray to Prevent Stroke Recurrence

NCT00012454
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack
Interventions
E-Selectin nasal spray
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis

NCT02067611
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
X0002, Placebo
Drug
Lead sponsor
Lina Xu
Industry
Eligibility
35 Years to 85 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Tempe, Arizona • Carmichael, California • Spring Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

NCT03290248
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions
B244 suspension, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

NCT05629338
View directory record Official record
Conditions
Coagulopathy, Hemorrhage
Interventions
Autologous Spray Dried Plasma
Combination Product
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 3 Interventional Results available

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

NCT05011396
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Garden Grove, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed No phase listed Observational

trūFreeze® Spray Cryotherapy Patient Registry

NCT01802203
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Dysplasia, Esophageal Neoplasm, Esophageal Stenosis, Bronchial Neoplasm, Stenosis of Bronchus or Trachea
Interventions
truFreeze Spray Cryotherapy
Device
Lead sponsor
US Endoscopy Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
La Jolla, California • Denver, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

NCT01880840
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

NCT01205880
View directory record Official record
Conditions
Psoriasis
Interventions
Calcitriol ointment, Clobetasol spray
Drug
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

NCT00163488
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02116309
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Rectal Indomethacin, Epinephrine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 19, 2026, 9:37 PM EDT
Recruiting Not applicable Interventional

Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE)

NCT07169799
View directory record Official record
Conditions
Gastric Antral Vascular Ectasia
Interventions
trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

NCT01401465
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide, mometasone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
Huntington Beach, California • Mission Veijo, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique

NCT02910934
View directory record Official record
Conditions
Malaria
Interventions
Actellic CS
Other
Lead sponsor
PATH
Other
Eligibility
6 Months and older
Enrollment
3,915 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 19, 2026, 9:37 PM EDT
Suspended Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes

NCT02785120
View directory record Official record
Conditions
Ischemic Stroke
Interventions
TF0023
Drug
Lead sponsor
Techfields Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
24
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Englewood, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

NCT04408183
View directory record Official record
Conditions
SARS-CoV 2, Infection
Interventions
GLS-1200, Placebo
Drug
Lead sponsor
GeneOne Life Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Philadelphia, Pennsylvania • Conroe, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

NCT04610801
View directory record Official record
Conditions
Covid19
Interventions
Nasal Spray
Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

NCT00658788
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 19, 2026, 9:37 PM EDT
Not listed Phase 3 Interventional

Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460
View directory record Official record
Conditions
Premature Ejaculation
Interventions
Placebo, Promescent Lidocaine Spray
Drug
Lead sponsor
Eugene Y Rhee, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 19, 2026, 9:37 PM EDT